Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30541663 | 1.00 | PTGS2 (0.38) | PTGS2GPR119PTGS1SYKRIPK2 | |
| SCHEMBL25366890 | 0.93 | HRH3 (0.36) | PTGS2GPR119PTGS1SYKRIPK2 | |
| SCHEMBL30541584 | 0.93 | HRH3 (0.36) | PTGS2GPR119PTGS1SYKRIPK2 | |
| SCHEMBL25366357 | 0.91 | PTGS2 (0.37) | PTGS2GPR119PTGS1 | |
| SCHEMBL25366282 | 0.89 | HRH3 (0.44) | PTGS2GPR119 | |
| SCHEMBL30541679 | 0.89 | HRH3 (0.44) | PTGS2GPR119 | |
| SCHEMBL25364439 | 0.88 | PTGS2 (0.36) | PTGS2GPR119PTGS1SYKRIPK2 | |
| SCHEMBL30541593 | 0.88 | PTGS2 (0.36) | PTGS2GPR119PTGS1SYKRIPK2 | |
| SCHEMBL25365541 | 0.86 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL25364449 | 0.86 | JAK3 (0.43) | PTGS2GPR119SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | claimed |
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | PTGS2 957/4885GPR119 79/4885PTGS1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.